Health Trials

Marginal Zone B-Cell Lymphoma

4

Review clinical trials related to Marginal Zone B-Cell Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Participants needed: 300
Trial details
Phase: Phase 2Age: Up to 60Biological sex: AllType: InterventionalSponsor: Masonic Cancer Center, University of MinnesotaUpdated: Jun 25, 2026Locations: 1
Eligibility criteria

Age: ≤ 60 years of age [+41]

Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease... [+8]

Read more
Status: Not yet recruiting

Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors

This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.

Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Centre Hospitalier de la côte BasqueUpdated: Jun 22, 2026
Eligibility criteria

Age ≥18 years [+4]

Known cognitive impairment [+2]

Read more
Status: Not yet recruiting

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

JWCAR239 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR239 in patients with B Cell Non-Hodgkin Lymphoma (B-NHL)

Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Jun 17, 2025Locations: 1
Eligibility criteria

Histologically confirmed B-NHL with immunohistochemical positivity for CD20 and/... [+6]

Lymphoma involving the central nervous system (CNS). [+12]

Read more